Anticholinergic Agents

  • Phil Lieberman
Part of the Current Clinical Practice book series (CCP)

Abstract

Anticholinergic agents, derived from plant alkaloids, have been used for medicinal purposes for hundreds of years. They were introduced to Western medicine by the British in the 1800s, and gained wide popularity as inhaled agents (smoked through pipes or cigarets) for the therapy of asthma and bronchitis during the 1800s and early 1900s. As adrenergic agents were developed their use declined. However, over the past three decades, there has been a renaissance in the use of anticholinergic agents for respiratory disorders. There are two reasons for their reintroduction into our therapeutic armamentarium. These are our advances in knowledge regarding the role of the parasympathetic nervous system in respiratory disease and the development of anticholinergic agents that have increased effectiveness with decreased side effects. This has been accomplished by alterations in the structure of the naturally occurring belladonna alkaloid, atropine. The major structural change, favorably altering the efficacy and side effect profile of atropine, is the introduction of a quaternary ammonium congener, ipratropium bromide (Fig. 1). The quaternary ammonium structure of ipratropium bromide differs from that of atropine in that the nitrogen atom is pentavalent and has a positive charge.

Keywords

Chronic Obstructive Pulmonary Disease Allergic Rhinitis Nasal Spray Obstructive Lung Disease Common Cold 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  1. Bone RC, ed. Interventions and strategies in patients with obstructive airways disease. Proceedings of a Symposium. Am J Med 1991; 91 (4A): 1S-46S.Google Scholar
  2. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial. Chest 1994; 105: 1411 - 1419.CrossRefGoogle Scholar
  3. Hayden FG, Diamond L, Wood PB, Korts DC, Wecker MT. Effectiveness and safety of intranasal ipratropium bromide in common colds. Ann Intern Med 1996; 125: 89 - 97.PubMedGoogle Scholar
  4. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: Comparison with ipratropium bromide alone. Chest 1995; 107: 401 - 405.PubMedCrossRefGoogle Scholar
  5. Meltzer EO and Spector SL. Anticholinergic therapy for allergic and nonallergic rhinitis and the common cold. J Allergy Clin Immunol. May 1995; 95 (No 5, PT 2 ): 1065 - 1152.Google Scholar
  6. Meltzer EO, Orgel HA, Bronsky EA, Findlay SR, Georgitis JW, Grossman J, Ratner P, Wood CC. Ipratropium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life, and nasal cytology. J Allergy Clin Immunol 1992; 90 (2): 242 - 249.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Phil Lieberman

There are no affiliations available

Personalised recommendations